A Randomized Controlled Trial of Structural Ecosystems Therapy for HIV Medication Adherence and Substance Abuse Relapse Prevention

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2010 Jun 12

PMID 20538417

Citations 16

Authors

Daniel J Feaster

Victoria B Mitrani

Myron J Burns

Brian E McCabe

Ahnalee M Brincks

Allan E Rodriguez

Deshratn Asthana

Michael S Robbins

Affiliations

Soon will be listed here.

Abstract

Background: Substance abuse in women with HIV/AIDS overshadows other priorities, including health care. Substance abuse may cause women to avoid health care systems and not adhere to their medication regimen.

Methods: A randomized controlled trial tested the efficacy of Structural Ecosystems Therapy (SET) relative to a psychoeducational Health Group (HG) in 126 HIV+ women in recovery. SET, a 4-month intervention, focused on building family support for relapse prevention and HIV medication adherence. Over 12-month follow-up, women were assessed for drug use and medication adherence every 2 months; CD4 T-cell count and HIV viral load were assessed every 4 months.

Results: Levels of drug use did not differ by condition. There was a significant difference in curvature of the rates of change in drug use with SET increasing and then decreasing and HG decreasing and then increasing. Women in SET were more likely to increase substance abuse services in response to relapse and separate from drug using household members than were women in HG. These two changes explained the decline in drug use observed within SET between 6 and 12 months. SET showed declines in medication adherence but increases in CD4 T-cell count relative to HG. The increase in CD4 T-cell count in SET was related to increasing proportions of women in SET taking antiretroviral medications.

Conclusion: The results of the trial were mixed. Women in SET did not show better drug use or medication adherence outcomes, but did show improvement in CD4 T-cell count and theoretical mechanisms of action on drug relapse.

Citing Articles

Predicting antiretroviral medication adherence among substance-using people with HIV: test and extension of the information-motivation-behavioral skills model.

Krishnan A, Ranjit Y, Zhou X, Altice F J Behav Med. 2025; .

PMID: 39924604 DOI: 10.1007/s10865-025-00557-y.

Complex solutions for a complex problem: A meta-analysis of the efficacy of multiple-behavior interventions on change in outcomes related to HIV.

Sunderrajan A, White B, Durantini M, Sanchez F, Glasman L, Albarracin D Health Psychol. 2021; 40(9):642-653.

PMID: 34435836 PMC: 8629832. DOI: 10.1037/hea0001088.

Pilot Randomized Controlled Trial of a Syndemics Intervention with HIV-Positive, Cocaine-Using Women.

Jemison D, Jackson S, Oni O, Cats-Baril D, Thomas-Smith S, Batchelder A AIDS Behav. 2019; 23(9):2467-2476.

PMID: 31407212 PMC: 6880306. DOI: 10.1007/s10461-019-02625-2.

Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: an evidence map.

Adam G, Di M, Cu-Uvin S, Halladay C, Smith B, Iyer S Syst Rev. 2018; 7(1):25.

PMID: 29391059 PMC: 5796491. DOI: 10.1186/s13643-018-0684-y.

A systematic review of the inclusion of mechanisms of action in NIH-funded intervention trials to improve medication adherence.

Edmondson D, Falzon L, Sundquist K, Julian J, Meli L, Sumner J Behav Res Ther. 2017; 101:12-19.

PMID: 29033097 PMC: 5800992. DOI: 10.1016/j.brat.2017.10.001.

References

Feaster D, Burns M, Brincks A, Prado G, Mitrani V, Mauer M . Structural Ecosystems Therapy for HIV+ African-American women and drug abuse relapse. Fam Process. 2010; 49(2):204-19. PMC: 4048062. DOI: 10.1111/j.1545-5300.2010.01318.x. View

Bogart L, Kelly J, Catz S, Sosman J . Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr. 2000; 23(5):396-404. DOI: 10.1097/00126334-200004150-00006. View

Dennis M, Scott C, Funk R . An experimental evaluation of recovery management checkups (RMC) for people with chronic substance use disorders. Eval Program Plann. 2018; 26(3):339-352. PMC: 6054319. DOI: 10.1016/S0149-7189(03)00037-5. View

Baker S, Beadnell B, Stoner S, Morrison D, Gordon J, Collier C . Skills training versus health education to prevent STDs/HIV in heterosexual women: a randomized controlled trial utilizing biological outcomes. AIDS Educ Prev. 2003; 15(1):1-14. DOI: 10.1521/aeap.15.1.1.23845. View

Chesney M, Ickovics J, Chambers D, Gifford A, Neidig J, Zwickl B . Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group.... AIDS Care. 2000; 12(3):255-66. DOI: 10.1080/09540120050042891. View

Feaster D, Brincks A, Mitrani V, Prado G, Schwartz S, Szapocznik J . The efficacy of Structural Ecosystems Therapy for HIV medication adherence with African American women. J Fam Psychol. 2010; 24(1):51-9. PMC: 2836493. DOI: 10.1037/a0017954. View

Mertens J, Flisher A, Satre D, Weisner C . The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients. Drug Alcohol Depend. 2008; 98(1-2):45-53. PMC: 2741640. DOI: 10.1016/j.drugalcdep.2008.04.007. View

Wei L, Lachin J . Properties of the urn randomization in clinical trials. Control Clin Trials. 1988; 9(4):345-64. DOI: 10.1016/0197-2456(88)90048-7. View

Szapocznik J, Feaster D, Mitrani V, Prado G, Smith L, Robinson-Batista C . Structural ecosystems therapy for HIV-seropositive African American women: effects on psychological distress, family hassles, and family support. J Consult Clin Psychol. 2004; 72(2):288-303. PMC: 1480817. DOI: 10.1037/0022-006X.72.2.288. View

10.

Prado G, Szapocznik J, Mitrani V, Mauer M, Smith L, Feaster D . Factors influencing engagement into interventions for adaptation to HIV in African American women. AIDS Behav. 2006; 6(2):141-51. PMC: 1464091. DOI: 10.1023/a:1015497115009. View

11.

Remien R, Stirratt M, Dolezal C, Dognin J, Wagner G, Carballo-Dieguez A . Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS. 2005; 19(8):807-14. DOI: 10.1097/01.aids.0000168975.44219.45. View

12.

Boyd C, Holmes C . Women who smoke crack and their family substance abuse problems. Health Care Women Int. 2002; 23(6-7):576-86. DOI: 10.1080/07399330290107340. View

13.

Lucas G, Cheever L, Chaisson R, Moore R . Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001; 27(3):251-9. DOI: 10.1097/00126334-200107010-00006. View

14.

Markowitz J, Spielman L, Sullivan M, Fishman B . An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. J Psychother Pract Res. 2000; 9(4):226-31. PMC: 3330614. View

15.

Moos R . Theory-based processes that promote the remission of substance use disorders. Clin Psychol Rev. 2007; 27(5):537-51. PMC: 1940243. DOI: 10.1016/j.cpr.2006.12.006. View

16.

Sherer R . Adherence and antiretroviral therapy in injection drug users. JAMA. 1998; 280(6):567-8. DOI: 10.1001/jama.280.6.567. View

17.

Mitrani V, Prado G, Feaster D, Robinson-Batista C, Szapocznik J . Relational factors and family treatment engagement among low-income, HIV-positive African American mothers. Fam Process. 2003; 42(1):31-45. PMC: 1480626. DOI: 10.1111/j.1545-5300.2003.00031.x. View

18.

Bangsberg D . Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006; 43(7):939-41. DOI: 10.1086/507526. View

19.

Traynor K . HIV treatment guidelines revised. Am J Health Syst Pharm. 2010; 67(2):94. DOI: 10.2146/news100006. View

20.

Mitrani V, Weiss-Laxer N, Ow C, Ross-Russell S, Burns M, Feaster D . Examining family networks of HIV+ women in drug recovery: challenges and opportunities. Fam Syst Health. 2009; 27(3):267-283. PMC: 2845531. DOI: 10.1037/a0017116. View